Risk assessment in chronic myelomonocytic leukemia (CMML).
about
An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesRecent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemiaAllogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.Immune thrombocytopenia in chronic myelomonocytic leukemia.Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in miceCytogenetic risk stratification in chronic myelomonocytic leukemia.Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.Impairment of IFN-alpha production capacity in patients with hepatitis C virus and the risk of the development of hepatocellular carcinomaAn International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults.Chronic myelomonocytic leukemia: Forefront of the field in 2015.Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms.Age-related mutations and chronic myelomonocytic leukemia.Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy.CMML: Clinical and molecular aspects.Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.A 27-Year-Old Patient Fulfilling the Diagnostic Criteria of Both CMML and JMML.An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States.Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms.Transformation of cytogenetically normal chronic myelomonocytic leukaemia to an acute myeloid leukaemia and the emergence of a novel +13, +15 double trisomy resulting in an adverse outcome.Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia.Acute leukaemoid reaction following cardiac surgery.Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System.A case-control study of chronic myelomonocytic leukemia (CMML) in Shanghai, China: evaluation of risk factors for CMML, with special focus on benzene.Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.Models of Prognostication in Chronic Myelomonocytic Leukemia.Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.Therapy for Chronic Myelomonocytic Leukemia in a New Era.Immunophenotypes of Chronic Myelomonocytic Leukemia (CMML) Subtypes by Flow Cytometry: A Comparison of CMML-1 vs CMML-2, Myeloproliferative vs Dysplastic, De Novo vs Therapy-Related, and CMML-Specific Cytogenetic Risk Subtypes.Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.Activity of azacitidine in chronic myelomonocytic leukemia.Guidelines for the diagnosis and management of adult myelodysplastic syndromes.
P2860
Q24622700-E4DF6491-24B6-4AA5-9727-21D59BB04E30Q28307278-81DDCC27-98FB-468F-96FC-2686446D972BQ30274942-8967684C-1FC0-4B5A-9B1E-A9863C8116A4Q30420638-F4A0B03B-F69B-4C1E-89BB-7302684118A8Q33406648-84B5311F-FE12-49DE-9195-2865CF0E6BBFQ33415834-DEA05FA6-D21E-45A3-9AB2-380B23AC2697Q34516262-60D2FE3E-6B7E-4D7B-B23E-5B50F14B56A7Q34612592-019E07CB-ABE1-4ED5-A09F-64E4F0F6545BQ35162458-08CE31E2-178A-4BFE-9968-77BEB600E8A6Q36388371-2E1D6202-1006-437E-903A-E0B5E6D847D5Q36497089-9A26B5B0-FC2B-4495-874E-07A3F14FB9DFQ36708989-7D22D5FF-A409-403D-BD74-2D353FDFC902Q36862497-F2C606D4-5D0F-45E8-AB32-DF424785053AQ36876853-7E076A5E-2804-4BA1-89D4-BEFC33E542DCQ37205584-EF7AA60C-D9B8-4C37-A6A4-9BFB48D467ADQ37395779-62ABCDDE-53F9-4B3E-8CD4-B845994F782AQ37940261-CC41E1F0-6CAC-49A5-ACB7-F06594ACFF8EQ38012085-9DFF0724-841F-4E63-B873-41FD4C9C921EQ38130476-7A792E7F-5260-449B-AC03-E1CE16FF4203Q38241774-C6757A59-846A-4B86-B35B-9A830E79F0C6Q38289057-FD0551B2-2786-49D0-9073-6690D749D430Q38689508-EE11AEC4-F262-421A-A7F3-6451EC24DCD6Q38859646-EDA46C79-FEE0-4B6A-B9C6-E80C7A5388F5Q38961829-0E1AE84D-FE5B-47DE-B353-3365FCD6C369Q39048645-B0CFC1F1-6608-464E-A539-E5C9A4A6240CQ39158385-3D10F73F-90A9-4615-8671-13823A7D59CEQ39601934-FD7F28F1-3EC2-4626-9F0D-A6F63EED4148Q40018421-996D727A-C360-47D9-A764-D1138F7F258AQ41609451-0EB507EE-ED1F-4D09-8CA9-D84A57647A15Q43004365-5E03533C-394D-4A9D-9FD8-1058616AB6FEQ43899490-839C8047-447C-4E57-A7A6-DD82A06D8CABQ44221702-84261EBE-038D-49AA-BFFC-3A70EDEA7A8BQ46373480-B21E39E0-EAA1-4567-B840-14275273A85AQ47731555-ADAF0E9F-4165-4B6D-A954-98B917865905Q47793309-70672FDF-084A-489C-B4EF-EC6171250B59Q47853133-DC34B0EA-A93B-4695-8130-58E1CE6106A1Q53066596-7B04576E-3A97-4F73-ADE0-434B348A24E2Q53123731-AF8E7BD4-4753-4370-8ECB-AFC7837D6AF2Q53152113-95ADB808-3FFF-49B5-AA38-F3EF035768BFQ54392826-F17A0D88-246D-426C-BE19-F61D60FB6DEC
P2860
Risk assessment in chronic myelomonocytic leukemia (CMML).
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Risk assessment in chronic myelomonocytic leukemia (CMML).
@en
Risk assessment in chronic myelomonocytic leukemia
@nl
type
label
Risk assessment in chronic myelomonocytic leukemia (CMML).
@en
Risk assessment in chronic myelomonocytic leukemia
@nl
prefLabel
Risk assessment in chronic myelomonocytic leukemia (CMML).
@en
Risk assessment in chronic myelomonocytic leukemia
@nl
P2093
P2860
P1433
P1476
Risk assessment in chronic myelomonocytic leukemia (CMML).
@en
P2093
Gattermann N
P2860
P304
P356
10.1080/1042819042000207271
P577
2004-07-01T00:00:00Z